16496 Federal Register / Vol. 87, No. 56 / Wednesday, March 23, 2022 / Notices 

violation of section 337 by the eight 

defaulting respondents and for a 

recommendation that the Commission 

issue a general exclusion order (‘‘GEO’’) 

and cease and desist orders (‘‘CDOs’’). 

See Complainants’ Motion for Summary 

Determination of Violation and for 

Recommended Determination on 

Remedy and Bonding. Skull Shaver 

accused Yiwu Xingye and Yiwu City of 

infringing claims 1–3 of the ’528 patent 

and the claim of the ’504 design patent. 

Id. at 5. It accused the other respondents 

of infringing only claim 1 of the ’528 

patent. Id. On June 7, 2021, OUII filed 

a response in support of Skull Shaver’s 

motion. See Commission Investigative 

Staff’s Response to Skull Shaver’s 

Motion for Summary Determination of 

Violation. No respondent filed a 

response to Skull Shaver’s motion. 

On September 23, 2021, OUII filed a 

notice of supplemental authority 

concerning the domestic industry 

requirement. On September 28, 2021, 

the ALJ issued an order (Order No. 31) 

ordering certain supplementation of 

Skull Shaver’s domestic industry 

analysis. On October 14, 2021, Skull 

Shaver submitted its supplement in 

response to Order No. 31. No other 

responses to Order No. 31 were filed. 

On November 18, 2021, the ALJ grantedin-part Skull Shaver’s motion for 

summary determination as the subject 

ID. 

The ID found that Skull Shaver owns 

the asserted patents, and that those 

patents are valid and enforceable. ID at 

3. The ID further found that although all 

respondents imported, sold for 

importation, or sold within the United 

States after importation at least one 

accused article, the only respondents 

whose articles infringe the asserted 

patents are Yiwu Xingye and Yiwu City. 

Id. at 3–4. The ID found no infringement 

as to the other respondents, whose 

products lack a second recess, see ID at 

51–52, in view of the ALJ’s construction 

of ‘‘recesses’’ as ‘‘indentations that are 

substantially concave surfaces,’’ id. at 

16 (citation omitted), and Skull Shaver’s 

forfeiture of an infringement theory 

under the doctrine of equivalents, id. at 

50 n.7. The ID found that personal 

jurisdiction is not necessary over each 

defaulting respondent, but that the 

defaulting respondents waived any 

opportunity to contest the allegation 

that personal jurisdiction exists. Id. The 

ID further found that Skull Shaver meets 

the technical prong and the economic 

prong of the domestic industry 

requirement. Id. at 4. As to remedy, the 

RD found that there is a widespread 

pattern of unauthorized use of the 

asserted patents and it is difficult to 

identify the source of these products; 

and that a GEO is necessary to prevent 

circumvention. Id. at 4. The RD also 

recommended issuance of CDOs against 

the two infringing respondents, who are 

presumed to maintain domestic 

inventories. RD at 80–81. The RD 

recommended a bond rate of one 

hundred percent (100%) because 

complete pricing information is not 

available. RD at 82. 

No petitions for review of the ID were 

filed. The Commission determined to 

review the ID’s findings concerning the 

economic prong of the domestic 

industry requirement, and not to review 

the ID’s findings on other issues. Notice, 

87 FR 990, 991 (Jan. 7, 2022). The 

review notice solicited written 

submissions, including on remedy, the 

public interest, and bonding from the 

parties, interested government agencies, 

and the public. Id. 

In response to the Commission notice, 

Skull Shaver and OUII each filed an 

opening submission and a reply. No 

other parties filed submissions. 

On review, the Commission has 

determined to affirm the ID’s finding 

that Skull Shaver has satisfied the 

economic prong of the domestic 

industry requirement, and the 

Commission thereby affirms the ID’s 

finding of a violation of section 337. 

The Commission finds that the RD’s 

recommended remedy is appropriate for 

the reasons set forth in the attached 

opinion. Accordingly, the Commission 

finds that the appropriate remedy is: (1) 

A general exclusion order prohibiting 

the entry of certain electric shavers and 

components and accessories thereof; 

and (2) cease and desist orders directed 

to Yiwu Xingye and Yiwu City. The 

Commission has determined that the 

public interest factors enumerated in 

section 337(d), (f), and/or (g), 19 U.S.C. 

1337(d), (f), (g), do not preclude the 

issuance of the GEO or the CDOs. 

The Commission has determined that 

a bond in the amount of one hundred 

percent (100%) of the entered value of 

the subject articles is required during 

the Presidential review period, 19 

U.S.C. 1337(j) for the reasons set forth 

in the RD and the attached Commission 

Opinion. The investigation is hereby 

terminated. 

While temporary remote operating 

procedures are in place in response to 

COVID–19, the Office of the Secretary is 

not able to serve parties that have not 

retained counsel or otherwise provided 

a point of contact for electronic service. 

Accordingly, pursuant to Commission 

Rules 201.16(a) and 210.7(a)(1) (19 CFR 

201.16(a), 210.7(a)(1)), the Commission 

orders that the Complainant complete 

service for any party without a method 

of electronic service noted on the 

attached Certificate of Service and shall 

file proof of service on the Electronic 

Document Information System (EDIS). 

The Commission’s orders and opinion 

were delivered to the President and the 

United States Trade Representative on 

the day of their issuance. 

The Commission vote for these 

determinations took place on March 17, 

2022. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in Part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: March 17, 2022. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2022–06122 Filed 3–22–22; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–985] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey Pharmaceutical Materials, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Johnson Matthey 

Pharmaceutical Materials, Inc., has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplementary Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before May 23, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 23, 2022. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 56 / Wednesday, March 23, 2022 / Notices 16497 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on February 28, 2022, 

Johnson Matthey Pharmaceutical 

Materials, Inc., 2003 Nolte Drive, West 

Deptford, New Jersey 08066–1742, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Marihuana ....................... 7360 I 

Tetrahydrocannabinols ... 7370 I 

Noroxymorphone ............ 9145 I 

Difenoxin ......................... 9168 I 

Amphetamine ................. 1100 II 

Methamphetamine .......... 1105 II 

Lisdexamfetamine .......... 1205 II 

Methylphenidate ............. 1724 II 

Nabilone ......................... 7379 II 

ANPP (4-Anilino-Nphenethyl-4-piperidine).8333 II 

Norfentanyl (N-phenyl-N- 

(piperidin-4-yl) 

propionamide).

8366 II 

Cocaine .......................... 9041 II 

Codeine .......................... 9050 II 

Dihydrocodeine ............... 9120 II 

Oxycodone ..................... 9143 II 

Hydromorphone .............. 9150 II 

Diphenoxylate ................. 9170 II 

Ecgonine ......................... 9180 II 

Hydrocodone .................. 9193 II 

Levorphanol .................... 9220 II 

Meperidine ...................... 9230 II 

Methadone ...................... 9250 II 

Methadone intermediate 9254 II 

Morphine ......................... 9300 II 

Thebaine ......................... 9333 II 

Opium tincture ................ 9630 II 

Oxymorphone ................. 9652 II 

Noroxymorphone ............ 9668 II 

Alfentanil ......................... 9737 II 

Remifentanil .................... 9739 II 

Sufentanil ........................ 9740 II 

Tapentadol ...................... 9780 II 

Fentanyl .......................... 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. In reference to drug codes 

7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06159 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–979] 

Importer of Controlled Substances 

Application: Sharp Clinical Services, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Sharp Clinical Services, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 22, 2022. Such 

persons may also file a written request 

for a hearing on the application on or 

before April 22, 2022. 

ADDRESSES: The DEA requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on February 2, 2022, Sharp 

Clinical Services, Inc. 2400 Baglyos 

Circle, Bethlehem, Pennsylvania 18020– 

8024, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

3,4- 

Methylenedioxymethamphetamine.

7405 I 

The company plans to import the 

listed control substances for clinical 

trials. No other activity for these drug 

codes is authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06161 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–984] 

Bulk Manufacturer of Controlled 

Substances Application: Siemens 

Healthcare Diagnostics, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Siemens Healthcare 

Diagnostics, Inc. has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to Supplementary 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before May 23, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 23, 2022. 

ADDRESSES: The Drug Enforcement 

Administration (DEA) requires that all 

comments be submitted electronically 


jspears on DSK121TN23PROD with NOTICES1